Limited coverage criteria – saxagliptin and saxagliptin-metformin

 

Return to Special Authority drug list 

Generic name	saxagliptin / saxagliptin-metformin
Strength & form	saxagliptin 2.5 mg/5 mg / saxagliptin-metformin 2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg tablet

Special Authority criteria	Approval period
As part of a combination treatment for type 2 diabetes mellitus: After inadequate glycemic control on maximum tolerated doses of dual therapy of metformin and a sulfonylurea OR dual therapy of metformin and an insulin	Indefinite

Practitioner exemptions

• None

Special notes

• Patients intolerant to a sulfonylurea may be considered for coverage
• Patients intolerant to glyburide may try another sulfonylurea (e.g., gliclazide, which is available through the Special Authority program)
• Patients who meet the limited coverage criteria for saxagliptin automatically receive coverage for linagliptin

Special Authority request form(s)

• Log in to eForms
• HLTH 5481 - Third-Line Anti-Diabetic Drugs (PDF, 672KB)